New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)

Scientists at the Max Planck Institute for Infection Biology, Berlin and at the University Clinics of Ulm have developed a putative vaccine candidate against Mycobacterium tuberculosis, the causative agent of tuberculosis. Their data have been published in the Proceedings of the National Academy of Sciences U.S.A. on April 28, 1998.

Although tuberculosis belongs to the "old" diseases, it still remains a significant global health problem. Tuberculosis is responsible for 3 million deaths annually - more than at any time-point before and more than any other infectious agent. Moreover, it has been estimated that half a billion people will suffer from tuberculosis by the year 2050. Already in 1927, a vaccine was developed which was termed bacille Calmette-Gurin (BCG) to honour the scientists who attenuated Mycobacterium bovis by more than 230 passages on bile glycerol agar. In many countries the only measure for tuberculosis control has been vaccination with BCG. General agreement exists that BCG can protect or at least ameliorate severe forms of tuberculosis in children. Yet, it seems to be of low or no protective value in adults.

M. tuberculosis belongs to the group of intracellular bacteria that replicate within the phagosomal vacuoles of resting macrophages and protection against tuberculosis depends on T cell-mediated immunity. Major histocompatiblity complex (MHC) class II-restricted CD4 T helper cells and MHC class I-restricted cytotoxic CD8 T cells are stimulated during M.tuberculosis infection, but the current BCG vaccine fails to prime CD8 T cells for tuberculosis prevention.

Over the last few years, Juergen Hess and Stefan H.E. Kaufmann from the Max Planck Institute for Infection Biology in Berlin and the University Clinics of Ulm developed recombinant ( r )- BCG strains which secrete pore-f

Contact: Juergen Hess

Page: 1 2

Related biology news :

1. Scientists Identify Molecular Target For Tuberculosis Drug Treatment
2. Scientists Unlock Mystery Behind Proteins That Keep Tuberculosis Bacteria Alive; Finding Leads To Research Into New Drug Treatments
3. Hope Clinic of Emory Vaccine Center receives CDC contract
4. Vaccines against foodborne disease on horizon
5. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
6. Vaccine technique shows potential against common form of lung cancer
7. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
8. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
9. Vaccine prevents stroke in rats
10. Vaccine puts blood-sucking ticks off their food
11. Vaccine protects against fatal West Nile complication

Post Your Comments:

(Date:1/10/2019)... ... January 10, 2019 , ... When Dr. James L. Sherley, ... was invited to contribute a chapter to the new book Perinatal Stem Cells: Research ... Asymmetrex’s effort to address a debilitating secret of stem cell medicine. For more ...
(Date:1/7/2019)... ... 07, 2019 , ... Concerto HealthAI, a technology leader in ... oncology and other key therapeutic areas, and its Chief Executive Officer, Dr. Jeff ... spanning the entire healthcare landscape, on January 8, 2019, at 2:30 p.m. in ...
(Date:1/4/2019)... , ... January 03, 2019 , ... Stay on top ... medical device and food industries. Access to all webinars is free, so be sure ... in your field! Visit http://www.xtalks.com to check out our upcoming webinars, or ...
Breaking Biology News(10 mins):
(Date:1/8/2019)... ... January 08, 2019 , ... The American Society of Gene and ... by a selection committee made up of industry leaders identified by the ASGCT board ... are mentored awards created to support ASGCT members designing transformative pilot studies in gene ...
(Date:1/4/2019)... ... January 02, 2019 , ... CellMax Life , a ... blood, has been named as a partner in Medigen Biotech’s upcoming cell therapy ... for cancer treatment, will use CellMax Life’s circulating tumor cell platform CMxTM, in ...
(Date:12/19/2018)... Md. (PRWEB) , ... December 19, 2018 , ... ... for Life Science, announces the validated release of Limfinity® version 7.1. The new ... important technical offering from RURO as 2018 comes to an end. , Validation ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... have been given the green light to immediately begin a clinical patient trial ... The medical devices bureau of Health Canada has granted what is called an ...
Breaking Biology Technology:
Cached News: